DGI:Knochen-, Gelenks- und Protheseninfektionen/Quellen: Difference between revisions

From Infektiopedia
imported>Brinkery
(Die Seite wurde neu angelegt: „== Quellen ==“)
 
imported>Bestem
Line 1: Line 1:
== Quellen ==
==Quellen==
 
# '''Herren    C,<span class="ve-pasteProtect" style="mso-spacerun:yes" data-ve-attributes="{&quot;style&quot;:&quot;mso-spacerun:yes&quot;}">  </span>von der Höh N, Dreimann M.'''    Diagnostik und Therapie der Spondylodiszitis S2k-Leitlinie.    AWMF-Registernummer: 151-001Stand: 26.August2020
# '''Berbari EF, Kanj SS, Kowalski TJ, ''et al''.''' 2015 Infectious Diseases    Society of America ('''IDSA''') clinical practice guidelines for the    diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis '''2015'''; '''61''':    e26-46.
# '''Groll AH, Buchheidt D, Heinz W,    Bellmann R, Cornely O, Höhl R, ''et    al.''''' S1 Leitlinie Diagnose und Therapie von Candida Infektionen:    Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft    (DMykG) und der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG).    S1-Leitlinie. AWMF-Registernummer 082 – 005. Stand 07/2020
# '''Cornely OA, Bassetti M, Calandra T,    Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC,    Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP,    Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G,    Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ'''; ESCMID    Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida    diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012    Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039. PMID: 23137135.
# '''Schaberg T, Bauer T, Brinkmann F, Diel    R, Feiterna-Sperling C, Haas W, ''et    al.''''' Tuberkulose im Erwachsenenalter. S2k-Leitlinie.    AWMF-Registernummer 020 – 019. Stand 06/2017
# '''Zimmerli W.''' Clinical    practice. Vertebral osteomyelitis. N Engl J Med. 2010 Mar    18;362(11):1022-9.
# '''Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO,    Alhejaili SF.'''    Antibiotic penetration into bone and joints: An updated review. Int J    Infect Dis. 2019 Apr;81:128-136. doi: 10.1016/j.ijid.2019.02.005. Epub 2019 Feb 14. PMID:    30772469.
# '''Stammschulte T, Isner C, Kern WV.''' Daptomycin    (Cubicin®) – aktuelle Diskussion der Einsatzgebiete und Dosierung.    Arzneiverordnung in der Praxis Band 44 Heft 2 April 2017
# '''Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich    F, Pathan R, Hamed K.''' Evaluation of Effectiveness and Safety of High-Dose Daptomycin:    Results from Patients Included in the European Cubicin(®) Outcomes    Registry and Experience. Adv Ther. 2015 Dec;32(12):1192-205. doi: 10.1007/s12325-015-0267-4.    Epub 2015 Nov 26. PMID: 26610384; PMCID: PMC4679787.
# '''Senneville E, Caillon J, Calvet B, Jehl F:''' Towards a definition of    daptomycin optimal dose: Lessons learned from experimental and clinical    data. Int J Antimicrob Agents 2016; 47: 12-19.
# '''Malizos K, Sarma J, Seaton RA et al.:''' Daptomycin for the treatment of    osteomyelitis and orthopaedic device infections:real-world clinical    experience from a European registry. Eur J Clin Microbiol Infect Dis 2016;    35: 111-118.
# '''Seaton RA, Gonzalez-Ruiz A, Cleveland KO et al.:''' Realworld daptomycin use across    wide geographical regions: results from a pooled analysis of CORE and    EU-CORE. Ann Clin Microbiol Antimicrob 2016; 15: 18.
# '''Gould IM, Miró JM, Rybak MJ.''' Daptomycin: the role of    high-dose and combination therapy for Gram-positive infections. Int J    Antimicrob Agents. 2013 Sep;42(3):202-10. doi:    10.1016/j.ijantimicag.2013.05.005. Epub 2013 Jul 8. PMID: 23845504.
# '''Lora-Tamayo J, Parra-Ruiz J, Rodriguez-Pardo D, et al.''' High doses of daptomycin (10    mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic    joint infection managed with implant retention: a comparative study. Diagn    Microbiol Infect Dis. 2014;80:66–71.28.
# '''Herrera S, Sorli L, Horcajada JP.''' High-dose daptomycin together with    rifampin as salvage therapy for prosthetic joint infections. Med Clin    (Barc). 2017;149:223–4.29
# '''Vossen MG, Gattringer R, Thalhammer F,    Militz M, Hischebeth G:''' 10. Knochen- und Gelenkinfektionen. In:    Bodmann K-F, Grabein B, Kresken M et al. Kalkulierte parenterale Initialtherapie    bakterieller Erkrankungen bei Erwachsenen - Update 2018. PEG S2k    Leitlinie. AwMF-Registernummer    082-006. Stand 25.07.2019. S.228-238.
# '''Izakovicova P,    Borens O, Trampuz A:''' Periprosthetic joint infection: current concepts and outlook.    efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092.
 
<br />

Revision as of 17:28, 21 January 2021

Quellen

  1. Herren C,  von der Höh N, Dreimann M. Diagnostik und Therapie der Spondylodiszitis S2k-Leitlinie. AWMF-Registernummer: 151-001Stand: 26.August2020
  2. Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis 2015; 61: e26-46.
  3. Groll AH, Buchheidt D, Heinz W, Bellmann R, Cornely O, Höhl R, et al. S1 Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG). S1-Leitlinie. AWMF-Registernummer 082 – 005. Stand 07/2020
  4. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039. PMID: 23137135.
  5. Schaberg T, Bauer T, Brinkmann F, Diel R, Feiterna-Sperling C, Haas W, et al. Tuberkulose im Erwachsenenalter. S2k-Leitlinie. AWMF-Registernummer 020 – 019. Stand 06/2017
  6. Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010 Mar 18;362(11):1022-9.
  7. Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF. Antibiotic penetration into bone and joints: An updated review. Int J Infect Dis. 2019 Apr;81:128-136. doi: 10.1016/j.ijid.2019.02.005. Epub 2019 Feb 14. PMID: 30772469.
  8. Stammschulte T, Isner C, Kern WV. Daptomycin (Cubicin®) – aktuelle Diskussion der Einsatzgebiete und Dosierung. Arzneiverordnung in der Praxis Band 44 Heft 2 April 2017
  9. Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K. Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience. Adv Ther. 2015 Dec;32(12):1192-205. doi: 10.1007/s12325-015-0267-4. Epub 2015 Nov 26. PMID: 26610384; PMCID: PMC4679787.
  10. Senneville E, Caillon J, Calvet B, Jehl F: Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data. Int J Antimicrob Agents 2016; 47: 12-19.
  11. Malizos K, Sarma J, Seaton RA et al.: Daptomycin for the treatment of osteomyelitis and orthopaedic device infections:real-world clinical experience from a European registry. Eur J Clin Microbiol Infect Dis 2016; 35: 111-118.
  12. Seaton RA, Gonzalez-Ruiz A, Cleveland KO et al.: Realworld daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob 2016; 15: 18.
  13. Gould IM, Miró JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013 Sep;42(3):202-10. doi: 10.1016/j.ijantimicag.2013.05.005. Epub 2013 Jul 8. PMID: 23845504.
  14. Lora-Tamayo J, Parra-Ruiz J, Rodriguez-Pardo D, et al. High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. Diagn Microbiol Infect Dis. 2014;80:66–71.28.
  15. Herrera S, Sorli L, Horcajada JP. High-dose daptomycin together with rifampin as salvage therapy for prosthetic joint infections. Med Clin (Barc). 2017;149:223–4.29
  16. Vossen MG, Gattringer R, Thalhammer F, Militz M, Hischebeth G: 10. Knochen- und Gelenkinfektionen. In: Bodmann K-F, Grabein B, Kresken M et al. Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018. PEG S2k Leitlinie. AwMF-Registernummer 082-006. Stand 25.07.2019. S.228-238.
  17. Izakovicova P, Borens O, Trampuz A: Periprosthetic joint infection: current concepts and outlook. efort Open Rev 2019; 4 482-494. DOI: 10.1302/2058-5241.4.180092.


Retrieved from "https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Knochen-,_Gelenks-_und_Protheseninfektionen/Quellen&oldid=1850"